Table 1

Patient demographics and clinical characteristicsa

Disease

Sex (n)

Race (n)

Mean age, years

(range)

Mean CLASI or CDASI score

Medications (patients, n)


DLE (n = 21)

Females, 16

Males, 5

AA, 12

White, 8

Hispanic, 1

45.0 (23 to 64)

8

Antimalarials, 18

Methotrexate, 2

Immunosuppressants, 5

Corticosteroids, 3

Dapsone, 1

Thalidomide, 1

SCLE (n = 10)

Females, 7

Males, 3

White, 9

Asian, 1

47.1 (20 to 64)

9.5

Antimalarials, 7

Immunosuppressants, 2

Corticosteroids, 2

Thalidomide, 4

TLE (n = 10)

Females, 8

Males, 2

AA, 1

White, 9

42.9 (25 to 57)

10.1

Antimalarials, 10

Methotrexate, 1

DM (n = 18)

Females, 15

Males, 3

AA, 1

White, 16

Asian, 1

49 (21 to 75)

14.7

Antimalarials, 10

Methotrexate, 6

Immunosuppressants, 6

Corticosteroids, 9

controls (n = 18)

Females, 10

Males, 8

AA, 4

White, 12

Asian, 2

31.2 (26 to 57)

N/A

N/A


aAA = African American; CDASI = Cutaneous Dermatomyositis Area and Severity Index; CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index; DLE = discoid lupus erythematosus; DM = dermatomyositis; N/A = not applicable; SCLE = subacute cutaneous lupus erythematosus; TLE = tumid lupus erythematosus.

Nabatian et al. Arthritis Research & Therapy 2012 14:R1   doi:10.1186/ar3549

Open Data